$-11.90
(Market cap
$38,661 Mln
Revenue (TTM)
$2,501 Mln
P/E Ratio
--
P/B Ratio
22.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-12.6 %
-
Industry P/E
44.79
-
EV/EBITDA
-26.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
143,215,382
10 Years Aggregate
CFO
$-1,528.27 Mln
EBITDA
$-2,147.13 Mln
Net Profit
$-2,244.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| 17.8 | 21.2 | 33.0 | 66.9 | 79.2 | 17.4 | 35.9 |
|
BSE Sensex
| -8.4 | 4.9 | 1.2 | -7.1 | 5.9 | 8.2 | 11.1 |
|
S&P 100
| 7.8 | 3.2 | 11.9 | 21.4 | 22.1 | 13.2 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
| 44.7 | 150.8 | 55.9 | -57.0 | -6.2 | 195.4 | 141.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Natera (NTRA)
|
270.0 | 38,661.0 | 2,500.9 | -226.3 | -11.1 | -15 | -- | 22.2 |
| 104.2 | 131,178.1 | 407,905.0 | 2,932.0 | 1.6 | 3.9 | 45.9 | 1.7 | |
| 232.8 | 14,729.2 | 13,835.1 | 781.4 | 14.3 | -- | 22.2 | 21.6 | |
| 110.2 | 10,927.8 | 6,066.4 | 609.2 | 18.6 | 16.7 | 19 | 4.4 | |
| 406.6 | 90,734.7 | 76,388.0 | 6,794.0 | 15.8 | -- | 14.1 | 291.3 | |
| 276.8 | 22,765.7 | 14,144.2 | 941.5 | 9.7 | 10.8 | 24.6 | 2.6 | |
| 207.4 | 23,030.4 | 11,278.0 | 1,024.0 | 14.7 | 13.3 | 23 | 3.1 | |
| 204.3 | 17,593.5 | 21,455.0 | 1,703.0 | 18.6 | 17.1 | 10.6 | 3.7 | |
| 168.6 | 9,853.3 | 5,274.0 | 363.4 | 9.2 | 16.2 | 27.5 | 4.2 | |
| 155.6 | 9,395.2 | 17,760.3 | 1,520.8 | 12.2 | 20.2 | 6.5 | 1.3 |
Shareholding Pattern
View DetailsAbout Natera (NTRA)
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of... treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar Read more
-
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
-
Co-Founder & Executive Chairman
Dr. Matthew Rabinowitz Ph.D.
-
Headquarters
Austin, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Natera (NTRA)
What is the current share price of Natera Inc (NTRA) Today?
The share price of Natera Inc (NTRA) is $269.95 (NASDAQ) as of 10-Jul-2026 16:00 EDT. Natera Inc (NTRA) has given a return of 79.23% in the last 3 years.
What is the current PB & PE ratio of Natera Inc (NTRA)?
Since, TTM earnings of Natera Inc (NTRA) is negative, P/E ratio is not available.
The P/B ratio of Natera Inc (NTRA) is 22.15 times as on 10-Jul-2026, a 550 premium to its peers’ median range of 3.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-150.47
|
18.29
|
|
2024
|
-103.68
|
16.52
|
|
2023
|
-17.19
|
9.76
|
|
2022
|
-7.22
|
5.60
|
|
2021
|
-18.32
|
13.23
|
What is the 52 Week High and Low of Natera Inc (NTRA)?
The 52-week high and low of Natera Inc (NTRA) are Rs 288.04 and Rs 131.81 as of 12-Jul-2026.
What is the market cap of Natera Inc (NTRA)?
Natera Inc (NTRA) has a market capitalisation of $ 38,661 Mln as on 10-Jul-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Natera Inc (NTRA)?
Before investing in Natera Inc (NTRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.